Pharmacogenetic Biomarkers of Response in Crohn's Disease

Overview

Journal Pharmacogenomics J

Specialties Genetics
Molecular Biology
Pharmacology

Date 2017 Jun 21

PMID 28631723

Citations 9

Authors

T M Linares-Pineda

M Canadas-Garre

A Sanchez-Pozo

M A Calleja-Hernandez

Affiliations

Soon will be listed here.

Abstract

Crohn's disease (CD) is a chronic condition, which affects the immune system. It can also affect any part of the digestive tract and be associated with external manifestations. The causes of the disease remain unknown, although it seems to be the result of a combination of factors, such as genetic predisposition, environment, lifestyle and the composition of the microbiota, among others. The treatment protocol begins with a change in eating and smoking habits, and is continued with different lines of treatment, including corticosteroids, immunomodulators and biologic therapy (infliximab and adalimumab), which have shown differences in response among patients, especially with biologic treatment. Several studies have considered the possibility that these differences in response are caused by the genetic variability of patients. Many genes have been investigated as potential predictors of response to biological drugs, such as ADAM17, ATG16L1, EMSY, CASP9, CCNY, CNTN5, FASLG, FCGR, NOD2, PTGER4, IL13, IL1B, IL27, IL11, IL17F, TNF and TNFR genes. In this review, we will gather the information on influence of gene polymorphisms investigated to date on response to biological drugs in CD patients.

Citing Articles

Single-Cell Network-Based Drug Repositioning for Discovery of Therapies against Anti-Tumour Necrosis Factor-Resistant Crohn's Disease.

Kwak M, Hwang C, Cha J, Jeon J, Yoon J, Park S Int J Mol Sci. 2023; 24(18).

PMID: 37762402 PMC: 10531326. DOI: 10.3390/ijms241814099.

Association between genetic variants and development of antibodies to infliximab: A cross-sectional study in Chinese patients with Crohn's disease.

Zhu K, Ding X, Chen Z, Xi Q, Pang X, Chen W Front Pharmacol. 2023; 14:1096816.

PMID: 36726584 PMC: 9885127. DOI: 10.3389/fphar.2023.1096816.

Uncovering Novel Pre-Treatment Molecular Biomarkers for Anti-TNF Therapeutic Response in Patients with Crohn's Disease.

Kwak M, Cha J, Jeon J, Yoon J, Park S J Funct Biomater. 2022; 13(2).

PMID: 35466218 PMC: 9036297. DOI: 10.3390/jfb13020036.

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.

Peyrin-Biroulet L, Sandborn W, Panaccione R, Domenech E, Pouillon L, Siegmund B Therap Adv Gastroenterol. 2021; 14:17562848211059954.

PMID: 34917173 PMC: 8669878. DOI: 10.1177/17562848211059954.

Multi-alleles predict primary non-response to infliximab therapy in Crohn's disease.

Zhang C, Tang J, Wang X, Lyu K, Huang M, Gao X Gastroenterol Rep (Oxf). 2021; 9(5):427-434.

PMID: 34733528 PMC: 8560039. DOI: 10.1093/gastro/goaa070.

References

Wisniewski H, Hua J, Poppers D, Naime D, Vilcek J, Cronstein B . TNF/IL-1-inducible protein TSG-6 potentiates plasmin inhibition by inter-alpha-inhibitor and exerts a strong anti-inflammatory effect in vivo. J Immunol. 1996; 156(4):1609-15. View

Germain A, Gueant R, Chamaillard M, Allen P, Bresler L, Gueant J . NOD2 gene variant is a risk factor for postoperative complications in patients with Crohn's disease: A genetic association study. Surgery. 2016; 160(1):74-80. DOI: 10.1016/j.surg.2016.01.013. View

Steenholdt C, Enevold C, Ainsworth M, Brynskov J, Thomsen O, Bendtzen K . Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2012; 36(7):650-9. DOI: 10.1111/apt.12010. View

Mahid S, Minor K, Stromberg A, Galandiuk S . Active and passive smoking in childhood is related to the development of inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13(4):431-8. DOI: 10.1002/ibd.20070. View

Lesley J, Gal I, Mahoney D, Cordell M, Rugg M, Hyman R . TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J Biol Chem. 2004; 279(24):25745-54. DOI: 10.1074/jbc.M313319200. View

Duan H, Orth K, Chinnaiyan A, Poirier G, Froelich C, He W . ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J Biol Chem. 1996; 271(28):16720-4. DOI: 10.1074/jbc.271.28.16720. View

Dignass A, Van Assche G, Lindsay J, Lemann M, Soderholm J, Colombel J . The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis. 2010; 4(1):28-62. DOI: 10.1016/j.crohns.2009.12.002. View

Kawaguchi M, Onuchic L, Li X, Essayan D, Schroeder J, Xiao H . Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J Immunol. 2001; 167(8):4430-5. DOI: 10.4049/jimmunol.167.8.4430. View

Moroi R, Endo K, Kinouchi Y, Shiga H, Kakuta Y, Kuroha M . FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics. 2013; 65(4):265-71. DOI: 10.1007/s00251-013-0679-8. View

10.

Mayer L, Kaser A, Blumberg R . Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease. Gastroenterology. 2012; 143(1):13-7. PMC: 3392152. DOI: 10.1053/j.gastro.2012.05.015. View

11.

Papamichael K, Gazouli M, Karakoidas C, Panayotou I, Roma-Giannikou E, Mantzaris G . Association of and gene polymorphisms with differential response to infliximab in a Greek cohort of Crohn's disease patients. Ann Gastroenterol. 2014; 24(1):35-40. PMC: 3959457. View

12.

Schall T, Lewis M, Koller K, Lee A, Rice G, Wong G . Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell. 1990; 61(2):361-70. DOI: 10.1016/0092-8674(90)90816-w. View

13.

Pflanz S, Timans J, Cheung J, Rosales R, Kanzler H, Gilbert J . IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002; 16(6):779-90. DOI: 10.1016/s1074-7613(02)00324-2. View

14.

Qiu W, de Bruin D, Brownstein B, Pearse R, Ravetch J . Organization of the human and mouse low-affinity Fc gamma R genes: duplication and recombination. Science. 1990; 248(4956):732-5. DOI: 10.1126/science.2139735. View

15.

Hugot J, Laurent-Puig P, Gower-Rousseau C, Olson J, Lee J, Beaugerie L . Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature. 1996; 379(6568):821-3. DOI: 10.1038/379821a0. View

16.

Sandborn W, Gasink C, Gao L, Blank M, Johanns J, Guzzo C . Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012; 367(16):1519-28. DOI: 10.1056/NEJMoa1203572. View

17.

Patel I, Attur M, Patel R, Stuchin S, Abagyan R, Abramson S . TNF-alpha convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-alpha. J Immunol. 1998; 160(9):4570-9. View

18.

Mahid S, Minor K, Soto R, Hornung C, Galandiuk S . Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006; 81(11):1462-71. DOI: 10.4065/81.11.1462. View

19.

Liu J, van Sommeren S, Huang H, Ng S, Alberts R, Takahashi A . Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015; 47(9):979-986. PMC: 4881818. DOI: 10.1038/ng.3359. View

20.

Thomas D, Gazouli M, Karantanos T, Rigoglou S, Karamanolis G, Bramis K . Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease. World J Gastroenterol. 2014; 20(13):3609-14. PMC: 3974528. DOI: 10.3748/wjg.v20.i13.3609. View